Regeneron Pharmaceuticals Inc. (REGN)

294.82
1.80 0.60
NASDAQ : Health Technology
Prev Close 296.60
Open 297.88
Day Low/High 293.53 / 299.71
52 Wk Low/High 281.89 / 543.55
Volume 344.00K
Avg Volume 879.80K
Exchange NASDAQ
Shares Outstanding 105.95M
Market Cap 32.55B
EPS 11.30
P/E Ratio 24.46
Div & Yield N.A. (N.A)

Latest News

Regeneron Pharmaceuticals Becomes #32 Most Shorted Nasdaq 100 Component, Replacing Citrix Systems

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Blackstone Group, Xilinx, Celgene, Nvidia, Exelixis, Moneygram and more.

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Jim Cramer thinks that, finally, bargain hunters are just saying, "Enough already! It can't be that bad."

12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction

12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction

Thanks to the stock market correction many world-class stocks are back down to attractive levels.

Regeneron And Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis (NASH)

Regeneron And Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis (NASH)

Collaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseases

Regeneron Genetics Center® Publication In New England Journal Of Medicine Identifies New Genetic Variant Providing Protection From Chronic Liver Disease

Regeneron Genetics Center® Publication In New England Journal Of Medicine Identifies New Genetic Variant Providing Protection From Chronic Liver Disease

Findings validate importance of large-scale human genetics effort undertaken by Regeneron Genetics Center; provide target for potential development of new medicines

New Opportunities in Biotech: Cramer's 'Off the Charts'

New Opportunities in Biotech: Cramer's 'Off the Charts'

The beaten down biotech sector may offer more opportunities in this newly volatile market environment.

Chopping a Way Back for the Bull: Cramer's 'Mad Money' Recap (Tuesday 3/21/18)

Chopping a Way Back for the Bull: Cramer's 'Mad Money' Recap (Tuesday 3/21/18)

Jim Cramer maps out what investors need to find a way back to the upside, including the Fed, interest rates and earnings.

EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial

EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Expect U.S. regulatory submission for diabetic retinopathy later this year

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Walt Disney Co., RH, Immunogen, and Advanced Micro Devices.

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

In the wake of Trump's blocking the Broadcom-Qualcomm deal, Jim Cramer ask if we should be worried that all of tech that wants to be big in China could be under pressure.

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Top Projects at Nation's Oldest and Most Prestigious STEM Competition for High School Seniors Have Potential Implications for Agricultural Science, Public Health and Medical Diagnosis

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Top Projects at Nation's Oldest and Most Prestigious STEM Competition for High School Seniors Have Potential Implications for Agricultural Science, Public Health and Medical Diagnosis

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Jim Cramer looks at the investment strategies you need to use throughout your life, especially in a volatile market.

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Jim Cramer asks: Is every one of these vexing VIX derivatives going to have to go bust before this torture ends? Looks like it.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Jim Cramer highlights Anthem, A.O. Smith, Tableau Software, Electro Scientific Industries, CRISPR Therapeutics.

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Jim Cramer says this is the scary process that gets us back to where we can maintain a real, not parabolic, advance.

Forty Of The Nation's Most Promising Young Scientists Named Finalists In Regeneron Science Talent Search 2018

Forty Of The Nation's Most Promising Young Scientists Named Finalists In Regeneron Science Talent Search 2018

Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. Science and Mathematics Competition for High School Seniors

Forty Of The Nation's Most Promising Young Scientists Named Finalists In Regeneron Science Talent Search 2018

Forty Of The Nation's Most Promising Young Scientists Named Finalists In Regeneron Science Talent Search 2018

Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. Science and Mathematics Competition for High School Seniors

Floor & Decor, Chegg, Core Labs, Cedar Fair: 'Mad Money' Lightning Round

Floor & Decor, Chegg, Core Labs, Cedar Fair: 'Mad Money' Lightning Round

Jim Cramer is bullish on Floor & Decor, Chegg, Core Labs, Cedar Fair, Newmark Group, First Solar.

Market's Animal Spirits Roar: Cramer's 'Mad Money' Recap (Thursday 1/11/18)

Market's Animal Spirits Roar: Cramer's 'Mad Money' Recap (Thursday 1/11/18)

Jim Cramer says this market's odd-couple behavior is worth investigating because it can push stocks even higher.

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

Jim Cramer highlights T-Mobile US, Take-Two Interactive, Activision Blizzard, Owens Corning and more.

Investors, Here's Your Big Chance: Cramer's 'Mad Money' Recap (Thurs 12/14/17)

Investors, Here's Your Big Chance: Cramer's 'Mad Money' Recap (Thurs 12/14/17)

Weakness has been a clarion call to sell for so many, when it's really the buying opportunity that so few people recognize.

TheStreet Quant Rating: C (Hold)